Get the Stockscreener App
7.33
2.53%
-0.19
Pre-market:
7.37
0.04
+0.55%
Omeros Corporation stock is traded at $7.33, with a volume of 1.50M.
It is down -2.53% in the last 24 hours and up +78.78% over the past month.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
See More
Previous Close:
$7.52
Open:
$7.54
24h Volume:
1.50M
Relative Volume:
0.47
Market Cap:
$498.85M
Revenue:
-
Net Income/Loss:
$-117.81M
P/E Ratio:
-3.8989
EPS:
-1.88
Net Cash Flow:
$74.30M
1W Performance:
-2.91%
1M Performance:
+78.78%
6M Performance:
-0.27%
1Y Performance:
+81.44%
1-Day Range:
$7.22
$7.54
1-Week Range:
$7.22
$8.05
52-Week Range:
$2.95
$13.60
Omeros Corporation Stock (OMER) Company Profile
Name
Omeros Corporation
Sector
Industry
Phone
206-676-5000
Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
7.33 | 511.78M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-25 | Initiated | H.C. Wainwright | Buy |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Dec-08-22 | Downgrade | UBS | Buy → Neutral |
| Nov-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-08-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-08-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-21 | Downgrade | Maxim Group | Buy → Hold |
| Oct-01-21 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-27-21 | Initiated | JP Morgan | Neutral |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Aug-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-18 | Initiated | Seaport Global Securities | Buy |
| Mar-23-18 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-05-18 | Downgrade | Needham | Buy → Hold |
| Nov-08-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-17-17 | Reiterated | Maxim Group | Buy |
| Mar-17-17 | Reiterated | Needham | Buy |
| Nov-16-16 | Reiterated | Wedbush | Outperform |
| Nov-10-16 | Reiterated | Needham | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Jun-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-02-16 | Reiterated | Needham | Buy |
| Feb-29-16 | Reiterated | Wedbush | Outperform |
| Nov-11-15 | Reiterated | Needham | Buy |
| Aug-18-15 | Reiterated | WBB Securities | Strong Buy |
| Aug-10-15 | Initiated | ROTH Capital | Buy |
View All
Omeros Corporation Stock (OMER) Latest News
Tools to monitor Omeros Corporation recovery probabilityCEO Change & Fast Momentum Stock Entry Tips - newser.com
Will Omeros Corporation stock recover faster than marketQuarterly Portfolio Summary & Smart Allocation Stock Tips - newser.com
What candlestick patterns are forming on Omeros CorporationTrend Reversal & Consistent Growth Stock Picks - newser.com
Published on: 2025-11-02 12:27:59 - newser.com
A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now? - AOL.com
Can Omeros Corporation stock resist market sell offsCPI Data & Stock Portfolio Risk Management - newser.com
Ranking Omeros Corporation among high performing stocks via toolsJuly 2025 Final Week & Verified Technical Signals - newser.com
Is Omeros Corporation a good long term investmentAnalyst Upgrades & Fast Growing Stocks - earlytimes.in
Can momentum traders help lift Omeros CorporationAnalyst Downgrade & Consistent Profit Trade Alerts - newser.com
Omeros Corporation stock outlook for YEAR2025 Market WrapUp & AI Based Buy and Sell Signals - newser.com
Published on: 2025-10-31 23:47:38 - newser.com
Is Omeros Corporation meeting your algorithmic filter criteriaCEO Change & Weekly Market Pulse Updates - newser.com
What data driven models say about Omeros Corporation’s futureWeekly Gains Report & Verified Swing Trading Watchlist - newser.com
Quantitative breakdown of Omeros Corporation recent move2025 Fundamental Recap & Weekly High Momentum Picks - newser.com
Omeros CorporationCommon Stock (Nasdaq:OMER) Stock Quote | PRN_FinancialWrapper | PR Newswire - FinancialContent
What technical signals suggest for Omeros Corporation stockJobs Report & Community Verified Watchlist Alerts - newser.com
Omeros Stock Soars After $2.1 Billion Licensing Deal with Novo Nordisk - MSN
Omeros (OMER) Price Target Increased by 12.22% to 34.34 - Nasdaq
Is Omeros Corporation (OMER) One of the Hot Stocks to Buy with Huge Upside Potential? - MSN
Will Omeros Corporation stock deliver long term returnsPortfolio Update Summary & Weekly High Return Forecasts - newser.com
Why Omeros Corporation stock is trending among retail tradersJuly 2025 Action & Free Fast Entry Momentum Trade Alerts - Fundação Cultural do Pará
Omeros Stock Logs Best Session Ever After HC Wainwright Doubles Target On Novo Nordisk Deal; Retail Sees Big Upside - MSN
Omeros Corporation Stock (OMER) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):